These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25845709)

  • 1. Impact of quality improvement measures on the delivery of allergy immunotherapy: a 2-year follow-up.
    Mattos JL; Ferguson BJ; Lee S
    Int Forum Allergy Rhinol; 2015 Jun; 5(6):513-6. PubMed ID: 25845709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining quality metrics and improving safety and outcome in allergy care.
    Lee S; Stachler RJ; Ferguson BJ
    Int Forum Allergy Rhinol; 2014 Apr; 4(4):284-91. PubMed ID: 24449697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylaxis: still a ghost behind allergen immunotherapy.
    Makatsori M; Calderon MA
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):316-22. PubMed ID: 24873937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergy immunotherapy safety: location matters!
    Cox L; Aaronson D; Casale TB; Honsinger R; Weber R
    J Allergy Clin Immunol Pract; 2013; 1(5):455-7. PubMed ID: 24565616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations in providing allergen immunotherapy in the office.
    Mattos JL; Lee S
    Curr Opin Otolaryngol Head Neck Surg; 2016 Jun; 24(3):226-30. PubMed ID: 27092905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
    Moingeon P; Mascarell L
    Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of home-based and office allergy immunotherapy: A multicenter prospective study.
    Hurst DS; Gordon BR; Fornadley JA; Hunsaker DH
    Otolaryngol Head Neck Surg; 1999 Nov; 121(5):553-61. PubMed ID: 10547469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.
    Wasserman RL; Factor JM; Baker JW; Mansfield LE; Katz Y; Hague AR; Paul MM; Sugerman RW; Lee JO; Lester MR; Mendelson LM; Nacshon L; Levy MB; Goldberg MR; Elizur A
    J Allergy Clin Immunol Pract; 2014; 2(1):91-6. PubMed ID: 24565775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions.
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    J Allergy Clin Immunol Pract; 2014; 2(2):161-7. PubMed ID: 24607043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy safety: what have we learned from surveillance surveys?
    Kannan JA; Epstein TG
    Curr Allergy Asthma Rep; 2013 Aug; 13(4):381-8. PubMed ID: 23636820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].
    Malling HJ
    Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors and management of systemic reactions induced by subcutaneous immunotherapy].
    Wen L; Wen Z; Yang N
    Zhonghua Yi Xue Za Zhi; 2014 Oct; 94(38):3001-4. PubMed ID: 25547703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the safety of immunotherapy.
    Rank MA; Bernstein DI
    J Allergy Clin Immunol Pract; 2014; 2(2):131-5. PubMed ID: 24607038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylaxis in the allergist's office: preparing your office and staff for medical emergencies.
    Wallace DV
    Allergy Asthma Proc; 2013; 34(2):120-31. PubMed ID: 23484886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.
    Caminati M; Dama AR; Djuric I; Montagni M; Schiappoli M; Ridolo E; Senna G; Canonica GW
    Expert Rev Clin Immunol; 2015 Feb; 11(2):233-45. PubMed ID: 25484197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.